ライフサイエンスコーパス: interleukin-11

1 tokines (e.g. leukemia inhibitory factor and interleukin 11).

2 rleukin 6 was about 10-fold more potent that interleukin 11.

3 inhibitory factor [LIF], oncostatin M [OSM], interleukin-11 and cardiotrophin-1) also potentiated the

4 Interleukin-11 and inhibitor of DNA-binding domain-1 gen

5 thesis also by using in vitro expansion with interleukin-11 and steel factor of lineage(-) c-kit(+) S

6 em cells that were activated in culture with interleukin-11 and steel factor were also CD38(-).

7 ) individually for 1 week in the presence of interleukin-11 and steel factor.

8 nhibitors include somatostatin, nefstatin-1, interleukin-11, and calcitonin gene-related peptide.

9 dies show the potential of recombinant human interleukin-11 as a treatment for chemotherapy-induced t

10 ry responses; furthermore, interleukin 6 and interleukin 11 can abrogate T-cell activation due to tri

11 ciliary neurotrophic factor, interleukin-6, interleukin-11, cardiotrophin-1, and leukemia inhibitory

12 Interleukin-11 concentrations were highest within gingiv

13 expression in primary breast tumours and low interleukin-11 correlates with relapse-free survival in

14 on of microRNA-30c inversely correlates with interleukin-11 expression in primary breast tumours and

15 ystems to investigate the contributions that interleukin 11 (IL-11) and IL-13 might make to airway re

16 Earlier we demonstrated that blocking of interleukin 11 (IL-11) by systemic administration of ant

17 t, we selected and isolated a mimic motif of interleukin 11 (IL-11) from prostate biopsies after an i

18 system and used this system to express human interleukin 11 (IL-11) in respiratory structures.

19 dulators of IFN response-betacellulin (BTC), interleukin 11 (IL-11), and IL-17F-that caused time-depe

20 ivalently, on days 1 and 15, with or without interleukin 11 (IL-11; 15 microg/kg per day on days 3 to

21 M (OSM), Ciliary Neurotrophic Factor (CNTF), Interleukin-11 (IL-11) and Cardiotrophin (CT-1).

22 ulating repair in MS lesions, and identified interleukin-11 (IL-11) as an astrocyte-derived factor th

23 The mechanisms of interleukin-11 (IL-11) cytoprotection in intestinal epit

24 Interleukin-11 (IL-11) is a growth factor that increases

25 Interleukin-11 (IL-11) is a thrombopoietic cytokine that

26 Interleukin-11 (IL-11) is a unique thrombopoietic growth

27 mary human fibroblasts, that upregulation of interleukin-11 (IL-11) is the dominant transcriptional r

28 l line, resulted in a prolonged elevation of interleukin-11 (IL-11) mRNA, which can be inhibited by p

29 The multifunctional cytokine, interleukin-11 (IL-11), ameliorates the intestinal radia

30 First, we showed that the expression of interleukin-11 (IL-11), an anti-inflammatory cytokine ma

31 n of another member of this cytokine family, interleukin-11 (IL-11), and components of its receptor (

32 easured the levels of thrombo-poietin (TPO), interleukin-11 (IL-11), and interleukin-6 (IL-6) in pati

33 However, in combination with interleukin-11 (IL-11), both FL and KL enhanced the prod

34 ukin-1beta (IL-1beta), interleukin-6 (IL-6), interleukin-11 (IL-11), oncostatin M (OSM), and leukemia

35 lopram was best predicted by a marker in the interleukin-11 (IL11) gene.

36 czki and colleagues report the importance of interleukin 11 in a variety of gastrointestinal malignan

37 ony-stimulating factor (GM-CSF) in 1991, and interleukin-11 in 1997.

38 to investigate the use of recombinant human interleukin-11 in patients with chemotherapy-induced thr

39 Because RANKL- and interleukin-11-induced OCL formation was also reduced in

40 Interleukin-11 is a pleotropic cytokine produced by lung

41 An interleukin-6 family member, interleukin-11 is identified as a secondary target of tw

42 Interleukin 6 and interleukin 11, known to activate STAT3 synergistically,

43 in 3, KN motif and ankyrin repeat domains 4, interleukin 11, NADPH oxidase 4, and BTB [POZ] domain co

44 mulating factor (G-CSF), erythropoietin, and interleukin-11 or G-CSF alone to mobilize stem cells.

45 The interleukin-11 receptor alpha (IL-11Ralpha) is a functio

46 -11 (IL-11), and components of its receptor (interleukin-11 receptor; IL-11R), ie, IL-11Ralpha (invol

47 Recombinant human interleukin 11 (rhIL-11) is a cytokine with thrombocytop

48 Recombinant human interleukin-11 (rhIL-11) has recently become available c

49 rformed a phase I trial of recombinant human interleukin-11 (rhIL-11) in women with breast cancer.

50 Recombinant human interleukin-11 (rhIL-11) is a multifunctional cytokine t

51 e therapeutic potential of recombinant human interleukin-11 (rhIL-11) was tested in a neutropenic rat

52 Recombinant human interleukin-11 (rhIL-11), a glycoprotein 130 (gp130)-sig

53 gation was to determine if recombinant human interleukin-11 (rhIL-11), known to downregulate several

54 e thrombopoietic cytokine, recombinant human interleukin-11 (rhIL-11), on megakaryocytopoiesis in vit

55 hematopoietic activity of recombinant human interleukin-11 (rhIL-11, [Neumega, Cambridge, MA]) in pa

56 the efficacy and safety of recombinant human interleukin-11 (rhIL-11; Neumega, Genetics Institute, In

57 binant epiregulin, amphiregulin, CX3CL1, and interleukin-11 significantly enhanced ureteric bud branc

58 Recombinant human interleukin-11 stimulates megakaryocytopoiesis in vitro

59 The other activities of recombinant human interleukin-11, such as its ability to ameliorate mucosi

60 poietic growth factors (, thrombopoietin and interleukin-11) to prevent or treat neonatal thrombocyto

61 the role of two cytokines, interleukin 6 and interleukin 11, which share the signal transducing subun